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The fetus can be considered to be a highly sensitivemodel of long-term physiologic pulsatile perfusion,
and fetal lamb preparations have been used extensively
to test different patterns of bypass flows or pharmaco-
logic manipulations.1-5 In previous experiments we
have observed that pulsatile flow could overcome the
progressive rise in peripheral and placental vascular
resistances generated by steady-flow fetal bypass, and
we have demonstrated that the use of 30 minutes of pul-
satile-flow bypass may help in preventing the onset of
fetal hypoxia in this setting.2
In a second study,3 we hypothesized that nitric oxide
(NO) production was increased under pulsatile flow
conditions by comparison with steady-flow bypass.
Objective: Pulsatile flow was shown to overcome the progressive rise in
peripheral and placental vascular resistances observed during steady-flow
bypass, this rise being counteracted by inhibition of nitric oxide synthase.
This study quantifies the release of endothelial vasoactive substances during
a 60-minute in utero model of fetal bypass.
Methods: Fetuses were randomly allocated into 1 of 2 groups (steady flow,
n = 8, or pulsatile flow, n = 13) and subjected to bypass through central can-
nulation and perfusion with either a centrifugal or pulsatile (125 beats ·
min–1) blood pump.
Results: Lactate concentration was high, starting at fetal exteriorization and
increasing during fetal preparation in the 2 groups. Once bypass was estab-
lished, the rise was significant only in the steady-flow group. Plasma nitric
oxide metabolites, similar before bypass, reached higher levels during pul-
satile flow at the end of bypass (99 ± 9 vs 82 ± 23 µmol · L–1; P = .037).
Levels of urinary nitric oxide metabolites were significantly higher in the
pulsatile-flow than in the steady-flow group (764 ± 143 vs 508 ± 240 µmol
· L–1; P = .005). Plasma cyclic guanosine monophosphate levels increased
after 30 minutes of bypass in the pulsatile-flow group (25 ± 18 vs 12 ± 8
pmol · mL–1; P = .004), and urinary cyclic guanosine monophosphate excre-
tion was higher in the pulsatile-flow group (517 ± 450 vs 118 ± 78 pmol ·
mL–1; P = .024). Plasma endothelin-1 levels increased in the 2 groups and
were higher in the steady-flow group at 30 minutes (27 ± 5 vs 23 ± 2 pg ·
mL–1; P = .04) and 60 minutes of bypass (39 ± 7 vs 32 ± 6 pg · mL–1; P =
.04). Plasma renin concentration increased significantly during bypass only
in the steady-flow group (26 ± 10 vs 57 ± 42 in ng A1 · mL–1 · h–1; P = .04).
Conclusions: Improved placental and peripheral perfusion during fetal pul-
satile-flow bypass may be mediated by preservation of fetal/maternal
endothelial nitric oxide biosynthetic mechanisms and/or decreased activation
of the fetal renin-angiotensin pathway.  (J Thorac Cardiovasc Surg
2000;120:770-7)
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Infusion of an inhibitor of NO synthase (Nω-nitro-L-
arginine) during the second half of a 60-minute period
of pulsatile bypass generated fetal systemic and pla-
cental vascular resistances at the level observed during
steady-flow bypass. Thus, we had indirect proof that
pulsatile flow enhances NO production during fetal
bypass. Still, we had not completed direct measure-
ments of either NO or NO metabolites.
In the current study, we have used a traditional model
of fetal bypass in utero and have measured fetal hemo-
dynamic parameters during a 60-minute bypass con-
ducted under pulsatile or steady flow. Under these cir-
cumstances, we measured directly the level of
endothelium-released vasoactive substances to confirm
our previous hypothesis.
Materials and methods
Protocol. The fetuses (n = 24) were randomly allocated
into 1 of the 2 groups according to the type of fetal bypass,
either steady flow (SF group, n = 8) or pulsatile flow (PF
group, n = 16). Three animals were excluded in the PF group
(1 because of major maternal hypoxemia and hypercapnia
during preparation, 1 because of severe fetal pulmonary hem-
orrhage, and 1 that was found dead from umbilical cord twist-
ing). Thus, the results concern only the remaining animals
(SF group, n = 8; PF group, n = 13).
All procedures and protocols performed in this study were
approved by the local animal care committee and in compli-
ance with the Guide of the National Veterinary School for
Laboratory Animal Studies.
Anesthesia and hemodynamic monitoring. Ile de France
ewes between 140 and 146 days’ gestation (term is 147 days)
were fasted for 36 to 48 hours before the operation. The animals
were placed in the supine position on an operating table after
induction of anesthesia with diazepam (0.25 mg · kg–1) and ket-
amine (5 mg · kg–1) intravenously administered in the jugular
vein. Ewes were intubated and connected to a volume-cycled
respirator (MMS 107 ventilator; MMS, Chelles, France) with a
respiratory rate of 10 cycles · min–1 and a tidal volume of 15 mL
· kg–1. A mixture of nitrous oxide and oxygen was simultane-
ously administered at a flow rate intended to keep the arterial
oxygen saturation at 99% and the arterial carbon dioxide ten-
sion (PCO2) within normal limits. Anesthesia was maintained
with 1% to 1.5% inspired halothane supplied by a Fluotec
vaporizer (Ohmeda Heath Care, West Yorkshire, England).
Expired gases (oxygen, carbon dioxide, nitrogen dioxide, and
halothane) were continuously monitored with a Hewlett-
Packard HP M1015B analyzer (Hewlett-Packard, Evry, France)
to optimally adjust volume and percentage of inspired gases. A
large-bore intravenous catheter (16 gauge) was inserted in the
maternal left jugular vein for fluid infusion to maintain adequate
uterine perfusion and to avoid fetal and maternal hypoglycemia.
An arterial line (18 gauge) was introduced in the maternal
femoral artery for maternal blood pressure monitoring and
blood gas sampling.
Fetal surgical procedure. After exposure of the uterus
through a low midline laparotomy and a small hysterotomy,
fetal surgery was carried out according to a previously
described technique.2,3,6 Ketamine (50 mg · kg–1) was admin-
istered intramuscularly to the fetus. Through a fetal neck inci-
sion, catheters were inserted into the common carotid artery
(20 gauge) for blood pressure monitoring and blood sampling
and into the jugular vein (18 gauge) for fetal infusion. The
umbilical cord was mobilized and a 4S to 6S ultrasonic flow
probe was carefully placed around the umbilical artery for
umbilical blood flow monitoring (T206 flowmeter; Transonic
Systems, Inc, Ithaca, NY). After exteriorization, avoiding
amniotic fluid losses, the fetus was placed on an isolating pad
and the temperature was constantly monitored by a rectal
probe. After a fetal midline sternotomy, the pericardium was
opened, suspended, and the heart was exposed. The main pul-
monary artery and the ascending aorta were dissected out,
and tapes were placed around the right and left pulmonary
arteries. An ultrasonic flowmeter (8S-10S) was placed around
the descending aorta, downstream to the ductus. A 300 U ·
kg–1 dose of heparin was administered intravenously to the
fetus. Normothermic bypass was instituted between the pul-
monary artery and right atrium. The bypass circuit consisted
of a bubble oxygenator (Hi-Flex D 700S; Dideco, Mirandola,
Italy) incorporating a heat exchanger and a venous reservoir
primed with 700 mL of freshly drawn heparinized adult sheep
donor blood diluted with 300 mL of Ringer’s lactate solution.
The gas flow through the oxygenator was a mixture of 21%
oxygen and 79% nitrogen and was adjusted to maintain fetal
oxygen and carbon dioxide tensions (PO2 and PCO2) within
normal limits. After connection to the circuit, both right and
left pulmonary arteries were occluded by the previously
placed tapes. Bypass was conducted for a 60-minute period
with either a centrifugal pump (Medtronic Bio-Medicus cen-
trifugal system, BP 50 mL; Medtronic, Inc, Eden Prairie,
Minn) or a Harvard pump (Harvard pulsatile blood pump,
1421A; Harvard Biosciences, Les Ulis, France) delivering
pulsatile flow at a rate of 125 beats · min–1. After the onset of
bypass, the fetal heart was electrically fibrillated to rule out
any contribution of the heart to the bypass flow and pulsatil-
ity. In each experiment the pump flow was adjusted to deliv-
er a fetal mean blood pressure within the physiologic range of
50 to 60 mm Hg. A third flowmeter was placed around the
bypass outlet tubing to measure the bypass flow. Because the
study was not aimed at fetal survival, we were not interested
in the late outcome of the fetus after bypass. Therefore, just
after cessation of bypass, the fetus was completely exterior-
ized, killed, and weighed. The ewe was then allowed to
recover under sedation and antibiotic prophylaxis, receiving
penicillin and colistin intramuscularly for 48 hours.
Data acquisition. Maternal and fetal hemodynamic pa-
rameters were continuously monitored with blood pressure
transducers (Abbott Transpac pressure set; Abbott Health-
care, Rungis, France) and a data acquisition system (Biopac
Data Acquisition System for Windows, ACK100
Acqknowledge Software for Windows; Harvard Bio-
sciences).
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Fetal hemodynamic parameters (pressure and flows) were
collected after exteriorization and insertion of a catheter into
the common carotid artery (baseline time, Tb), before onset
of bypass (cannulation time, Tc), and every 10 minutes after
initiation of bypass (T10-T60). Fetal systemic vascular resis-
tances were therefore calculated by dividing mean fetal arte-
rial blood pressure by corresponding pump flow, and placen-
tal vascular resistances were calculated by dividing the same
numerator by the corresponding placental blood flow. Values
were indexed on the fetal weight in kilograms.
Blood gases sampled from the fetal carotid artery were col-
lected at Tb, Tc, T10, T30, and T60 and immediately ana-
lyzed (PaO2, PaCO2, CO3H–1, oxyhemoglobin saturation, and
pH) on a Radiometer 2400 gas analyzer (ABL 330;
Radiometer A/S, Copenhagen, Denmark). Fetal hemoglobin
concentration was measured with a hemoglobin photometer
(HemoCue, Ängelholm, Sweden) at Tb, T10, and at the end
of bypass. Plasma sampling for osmolality, endothelin-1,
plasma renin concentration (PRC), and cyclic guanosine
monophosphate (cGMP) measurements were made immedi-
ately after the beginning of bypass and at 30 and 60 minutes
of bypass. For technical reasons NO metabolites were sam-
pled at the beginning and at the end of bypass. Arterial blood
samples (4.5 mL) were withdrawn into ethylenediamine-
tetraacetic acid glass tubes and immediately stored in ice.
Blood samples were then centrifuged at 1250g and 4°C for 10
minutes, and plasma was stored at –20°C until assayed.
Endothelin-1 was determined by radioimmunoassay.6 Nitrate
assays were performed after dilution with distilled water and
incubation with nitrate reductase and flavine adenosine.6
PRC was measured by radioimmunoassay, after incubation of
plasma with an excess of angiotensinogen.7 PRC was
expressed as nanograms of angiotensin 1 per milliliter of
plasma and hour of incubation (ng A1 · mL–1 · h–1); cGMP
was measured by radioimmunoassay8 and expressed as pico-
moles per milliliter (pmol · mL–1) (Kit Nex 133; NEN Life
Sciences Products, Paris, France).
Urinary samples for measurement of osmolality, NO
metabolites, cGMP, and creatinine were collected in the 2
groups at the end of the procedure by a fetal bladder puncture
and collection of the residual urine. Samples were stored at
–20°C until assayed.
Blood was collected on fluoride ethylenediaminetetraacetic
acid at Tb, T10, and T60, was centrifuged, and enzymatic
determination of lactate was performed immediately on plas-
ma samples (Lactate PAP; Biomerieux, Marcy-L’Etoile,
France).
Statistical analysis. Data were stored on a spreadsheet data-
base with a Power Macintosh 7600/132 computer (Apple
Computer, Cupertino, Calif) and then analyzed with a statisti-
cal package (StatView; Abacus Concepts, Inc, Berkeley, Calif).
Values were expressed as mean ± SD. Between-group differ-
ences were compared with 1-way analysis of variance and
repeated-measures 2-way analysis of variances. Within-group
differences were analyzed with t tests for dependent samples.
Statistical significance was established at the 5% level.
Results
The 2 groups were comparable with regard to the
average weight of ewes (SF group, 65 ± 17 kg; PF
group, 74 ± 18 kg) and fetuses (SF group, 4.2 ± 1 kg;
PF group, 4.1 ± 0.8 kg).
Arterial blood gases. The fetal values of arterial pH,
PCO2, PO2, CO3H–1, and oxyhemoglobin saturation
were not significantly different between groups (Table
I). The pH and CO3H–1 values decreased significantly
(respectively, P = .004 and P = .0012) only in the SF
group, as a consequence of metabolic acidemia devel-
Table I.  Values of fetal blood gases before and during bypass
Group After extraction Before bypass 10-min bypass 30-min bypass 60-min bypass 
pH
SF 7.25 ± 0.08 7.23 ± 0.07 7.23 ± 0.8 7.21 ± 0.07 7.21 ± 0.09*
PF 7.24 ± 0.07 7.25 ± 0.06 7.25 ± 0.08 7.25 ± 0.08 7.23 ± 0.1
PaO2 (mm Hg)
SF 19.1 ± 3.5 22.4 ± 7.2 68.7 ± 27.0 45.4 ± 13.4 59.0 ± 25.4
PF 22.0 ± 4.7 21.1 ± 4.4 50.2 ± 16.7 52.6 ± 17.9 44.7 ± 10.6
PaCO2 (mm Hg)
SF 34.7 ± 8.2 41.0 ± 8.5 31.7 ± 9.1 32.7 ± 8.2 32.5 ± 10.9
PF 40.8 ± 10.9 40.8 ± 12.7 33.9 ± 13.0 33.9 ± 12.7 32.3 ± 10.8
CO3H–1 (mmol · L–1)
SF 17.2 ± 4.1 16.8 ± 3.2 13.3 ± 4.2 13.9 ± 3.9 12.7 ± 3.2*
PF 15.5 ± 4.9 15.6 ± 3.8 14.7 ± 2.8 14.6 ± 2.5 14.0 ± 3.6
SaO2 (%)
SF 15.8 ± 5.4 22.3 ± 11.1 62.1 ± 28.4 54.7 ± 20.2 70.7 ± 20.6
PF 21.3 ± 7.5 19.6 ± 6.4 60.2 ± 20.7 66.1 ± 18.1 61.4 ± 15.5
PF, Pulsatile flow; SF, steady flow; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; CO3H-1, bicarbonate; SaO2, arterial oxygen tension; values
are given as mean ± SD.
*Within group differences, between “after extraction” and “60-min bypass.”
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oping between the exteriorization of the fetus and the
end of bypass. Lactate concentration was high right
after fetal exteriorization in both groups (Fig 1) and
continued to increase significantly during fetal prepara-
tion and cannulation in the 2 groups (SF group, P =
.0002; PF group, P < .0001). Once under bypass, the
rise was significant only in the SF group (P = .049).
After induction of anesthesia, hemoglobin values
were similar in the 2 groups (SF group, 12.8 ± 1.5 g ·
dL–1; PF group, 12.6 ± 1.2 g · dL–1) and decreased at
the beginning of bypass due to the priming dilution. It
remained stable afterward throughout the experiment
(SF group, 9.6 ± 0.8 g · dL–1; PF, 9.7 ± 0.9 g · dL–1).
Hemodynamics. There were no significant differ-
ences in either mean or differential blood pressure
between the 2 groups during fetal extraction (SF group,
63 ± 10 mm Hg and 28 ± 11 mm Hg; PF group, 65 ± 7
mm Hg and 26 ± 5 mm Hg) or just before bypass (PF
group, 59 ± 9 mm Hg and 23 ± 7 mm Hg; SF group, 61
± 6 mm Hg and 24 ± 5 mm Hg). During bypass the
mean blood pressure was comparable in the 2 groups,
set around 60 mm Hg, according to the protocol (Table
II). In the PF group, mean differential pressure during
bypass was 13.8 ± 2.6 mm Hg (13-15 mm Hg). Heart
rate was similar in the 2 groups during fetal exterior-
ization (SF group, 142 ± 20 beats · min–1; PF group,
128 ± 21 beats · min–1) and before bypass (SF group,
148 ± 18 beats · min–1; PF group, 135 ± 25 beats ·
min–1). Since the heart was fibrillating in each group
during bypass, the pulse pressure disappeared in the SF
Fig 1. Fetal plasma level of lactate (mmol · L–1):
Measurements were made after fetal exteriorization, on
bypass, and at the end of bypass. Black circle, Within-group
differences, P < .05.
Fig 2. Mean pump flow evolution (mL · min–1 · kg–1) and
between-group comparison. T10, 10 minutes of bypass; T60,
60 minutes of bypass. *Intergroup differences, pulsatile-flow
versus steady-flow group; P < .05.
Table II.  Values of fetal blood pressure before and during bypass
After Before 10-min 20-min 30-min 40-min 50-min 60-min
Group extraction bypass bypass bypass bypass bypass bypass bypass
SAP (mm Hg)
SF 80 ± 16 72 ± 10 58 ± 9 57 ± 6 59 ± 10 60 ± 10 62 ± 10 59 ± 9
PF 82 ± 9 76 ± 8 68 ± 8* 70 ± 9* 68 ± 7* 70 ± 8* 71 ± 6* 72 ± 6*
MAP (mm Hg)
SF 63 ± 10 59 ± 9 57 ± 9 57 ± 6 58 ± 9 60 ± 10 61 ± 10 59 ± 9
PF 65 ± 7 61 ± 6 60 ± 7 61 ± 8 61 ± 8 62 ± 8 62 ± 6 61 ± 6
DAP (mm Hg)
SF 53 ± 7 49 ± 3 56 ± 9 56 ± 6 58 ± 9 58 ± 10 60 ± 10 58 ± 10
PF 56 ± 7 53 ± 6 53 ± 6 55 ± 8 54 ± 7 56 ± 8 59 ± 6 58 ± 5
PP (mm Hg)
SF 28 ± 11 23 ± 7 0.5 ± 0.9 0.2 ± 0.3 0.4 ± 0.7 0.5 ± 0.3 0.5 ± 0.2 3 ± 3
PF 26 ± 5 24 ± 5 15 ± 3* 15 ± 3* 14 ± 3* 14 ± 3* 13 ± 2* 13 ± 3*
SAP, Systolic arterial pressure; MAP, mean arterial pressure; DAP, diastolic arterial pressure; PP, pulse pressure or differential pressure; PF, pulsatile flow; SF, steady
flow. Values are given as mean ± SD. 
*P < .05.
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group at initiation of bypass and the pump rate was at
125 beats · min–1 in the PF group, according to the pro-
tocol.
Mean pump flow was significantly higher in the PF
than in the SF group after 20 minutes of bypass and
until the end of bypass (P = .0004) (Fig 2). Distal fetal
aortic flow rate was significantly higher in the PF
group than in the SF group after 40 minutes of bypass
and until the end of bypass (P = .0376) (Fig 3). In both
groups the umbilical flow decreased significantly at
the beginning of bypass (SF group, P = .001; PF
group, P < .0001) but was significantly higher after 40
minutes of bypass in the PF group than in the SF group
(P = .030) (Fig 4).
Fetal systemic vascular resistances were significant-
ly lower after 40 minutes of bypass in the PF group 
(P = .402) (Fig 5). Placental vascular resistances
increased in the 2 groups immediately after the begin-
ning of bypass (SF group, P = .0086; PF group, P <
.0001). After 40 minutes of bypass and until the end of
bypass, the placental vascular resistances were signifi-
cantly higher in the SF group than in the PF group (P =
.0271) (Fig 6).
Release of vasoactive substances. Fetal plasma
(Table III) and urinary osmolality (SF group, 221 ± 77
mOsm · kg–1 H2O; PF group, 231 ± 72 mOsm · kg–1
H2O) were not significantly different between the
groups before or after bypass. Total fetal urinary creati-
nine excretion was higher in the PF group (SF group,
207 ± 70 mg · L–1; PF group, 340 ± mg · L–1; P = .0427).
Plasma NO metabolites were also similar before
bypass, increased significantly during bypass in the 2
Fig 3.  Mean distal aortic flow evolution (mL · min–1 · kg–1)
and between-group comparison. Tb, Baseline time; Tc, can-
nulation time; T10 to T60, every 10 minutes after initiation of
bypass. *Intergroup differences, pulsatile-flow versus steady-
flow group; P < .05.
Fig 4. Mean umbilical flow evolution (mL · min–1 · kg–1) and
between-group comparison. Tb, Baseline time; Tc, cannula-
tion time; T10 to T60, every 10 minutes after initiation of
bypass. *Intergroup differences, pulsatile-flow versus steady-
flow group; P < .05.
Fig 5.  Mean fetal systemic vascular resistances evolution
(mm Hg · mL–1 · min–1 · kg–1) and between-group compari-
son. T10, 10 minutes of bypass; T60, 60 minutes of bypass.
*Intergroup differences, pulsatile-flow versus steady-flow
group; P < .05.
Fig 6.  Mean placental vascular resistances evolution (mm Hg
· mL–1 · min–1 · kg–1) and between-group comparison. Tb,
Baseline time; Tc, cannulation time; T10 to T60, every 10
minutes after initiation of bypass. *Intergroup differences,
pulsatile-flow versus steady-flow group; P < .05.
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groups (SF group, P = .0019; PF group, P < .0001), and
were significantly higher in the PF group at the end of
bypass (PF group, 99 ± 9 µmol · L–1; SF group, 82 ± 23
µmol · L–1; P = .037). Total urinary NO metabolites
were significantly higher in the PF than in the SF group
(764 ± 143 µmol · L–1 vs 508 ± 240 µmol · L–1; P =
.005). Plasma cGMP level increased significantly
immediately after 30 minutes of bypass in the PF group
(P = .004). Urinary cGMP excretion was significantly
higher in the PF group (PF group, 517 ± 450 pmol ·
mL–1; SF group, 118 ± 78 pmol · mL–1; P = .024).
Plasma endothelin-1 levels were similar before bypass
and increased significantly in both groups after 30 (SF
group, P = .0056; PF group, P < .0001) and 60 minutes
of bypass (SF group, P = .0023; PF group, P < .0001).
Plasma endothelin-1 concentrations were significantly
higher in the SF group at 30 minutes (SF group, 27 ± 5
pg · mL–1; PF group, 23 ± 2 pg · mL–1; P = .04) and 60
minutes of bypass (SF group, 39 ± 7 pg · mL–1; PF
group, 33 ± 6 pg · mL–1; P = .04). Although PRC
increased significantly between the onset and the end of
bypass in the SF group only (26 ± 10 ng A1 · mL–1 · h–1
vs 57 ± 42 ng A1 · mL–1 · h–1; P = .04), intergroup dif-
ferences were not significant at the end of bypass.
Discussion
As demonstrated by many studies, fetal bypass with
standard steady-flow pumps rapidly triggers a severe
placental dysfunction dominated by a strong vasocon-
strictive reaction. Thus, some authors1,5,9 have used
pharmacologic manipulations (generally based on
vasodilators) to overcome the rise in placental vascular
resistances, with subsequent decreased placental blood
flow and acidosis. Our approach has been more on the
hemodynamic side in trying to use the potentially ben-
eficial effects of pulsatile flow on global endothelial
function.
The current study generally confirms the hemody-
namic and oximetric data obtained by our previous
experiments3: after 1 hour of in utero bypass, overall
fetal endothelial function is better preserved under pul-
satile than steady flow. Pulsatile flow prevents the drop
in placental flow and limits the rise in placental vascu-
lar resistance observed with steady flow. We2 had also
hypothesized that the addition of pulsatile flow during
fetal bypass, through the shear stress of blood on the
arterial wall,10,11 acted by stimulation of the NO
release. However, at the time of the last study,3 evi-
dence of enhanced NO release from the endothelium
with pulsatile-flow bypass was only indirectly avail-
able. This was accomplished through Nω-nitro-L-argi-
nine blockade. The currently available direct measure-
ments of endothelium-released vasoactive substances
and their metabolites add to the evidence of the benefi-
cial effects of pulsatility during fetal bypass.
After discussing the role of the main substances
involved during the typical 60-minute bypass period
(NO-cGMP, endothelin-1, renin-angiotensin), we will
also envision the limitations still attached to this type of
perfusion, along with the possible various modalities of
fetal bypass.
NO is the physiologic activator of the soluble
guanylate-cyclases responsible for cGMP produc-
tion, and the levels of plasma and urinary NO and of
urinary cGMP concentration were significantly high-
er in the PF group. These facts confirm that the use of
pulsatile flow appears to be better than nonpulsatile
flow in preserving the NO biosynthetic pathway. This
is also concordant with the work of Reddy and asso-
ciates,12 who compared the vasoactive effects of 2
vasodilators, acetylcholine (endothelium-dependent)
and nitroprusside (endothelium-independent) before
and after bypass to evaluate the ability of the
endothelium to produce NO: steady-flow bypass gen-
Table III.  Vasoactive substance release and plasma osmolality level during continuous (SF) or pulsatile bypass
flow (PF)
Start bypass 30-min bypass 60-min bypass
SF PF SF PF SF PF
PRC (ng A1 · mL–1 · h–1) 26 ± 10 26 ± 13 44 ± 36 31 ± 16 57 ± 42* 32 ± 19
NO2-NO3 (µmol · L–1) 68 ± 24 74 ± 11 82 ± 23* 99 ± 9*†
cGMP (pmol · mL–1) 12 ± 5 12 ± 8 20 ± 12 25 ± 18* 22 ± 17 25 ± 10*
Endothelin-1 (pg · mL–1) 18 ± 5 15 ± 3 27 ± 5* 23 ± 2*† 39 ± 7*‡ 33 ± 6*†‡
Plasma osmolality (mOsm · kg–1 H2O) 308 ± 10 298 ± 15 311 ± 7 306 ± 6 308 ± 10 307 ± 8
PRC, Plasma renin concentration; NO2-NO3, nitric oxide metabolites; cGMP, cyclic guanosine monophosphate. 
*Within group differences between “start bypass” and “30-min bypass” and “start bypass” and “60-min bypass.”
†Intergroup differences.
‡Within group differences between 30-min and 60-min bypass.
erates a selective impairment of endothelium-depen-
dent vasodilatation.
Similarly, pharmacologic activators of the soluble
guanylate-cyclases, like nitro-compounds nitroprusside
or nitroglycerin, were commonly used during fetal
bypass by other authors1,5 to avoid hypertension due to
high steady blood flows (400 mL · kg–1). The addition
of pulsatile-flow bypass has a similar effect and seems
to be well tolerated (60 minutes in our last 2 series vs
30 minutes in other reports).
Endothelin-1, the most potent vasoconstrictor pep-
tide,13 is also known to be an important regulator of
placental vascular tone.14,15 In the current study, the
plasma level of endothelin-1 at the beginning of
bypass, as well as its rise after 30 minutes of bypass,
were similar to those observed in the Reddy study.12
These authors also observed that the rise in placental
resistance during steady-flow fetal bypass was limited
after injection of a nonspecific endothelin-1 receptor
blocker (PD 145065). In the current study, the plasma
measurement of endothelin-1 at 60 minutes was signif-
icantly higher than the initial level at the beginning of
bypass in the 2 groups but was also significantly high-
er in the SF group.
Several reports have also brought some evidence of
an active renin-angiotensin system in the human fetal
circulation that may modulate placental perfusion and
function under physiologic conditions.16 When com-
pared with the value given in reference before and after
hemorrhage in fetal sheep,17 the PRC on bypass was
high, even in the PF group. Even though levels of renin-
angiotensin activity measured between groups were not
significantly different, there was a significant increase
of PRC in the SF group. Is this difference due to a pri-
mary endothelial dysfunction or a widespread response
to increased fetal renin-angiotensin activity?
Some arguments will support the hypothesis of a
primary bypass-induced endothelial dysfunction that
in turn triggers a stimulation of the renin-angiotensin
mechanism. In glomerular arterioles, endothelial and
juxtaglomerular cells are closely related. NO has been
shown to inhibit renin secretion.18 Therefore,
endothelial cells, when stimulated through shear
stress to produce NO, could also represent the
intrarenal baroreceptors. Meanwhile, recent studies19
have shown that on the top of a baseline, endothelin-
dependent vasoconstrictive tonus, there is a positive
interaction between angiotensin II and endothelin-1.
The latter was significantly increased in our study
during nonpulsatile bypass.
In support of the hypothesis that endothelial dysfunc-
tion is actually due to renin-angiotensin system activi-
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ty, previous studies20 have shown a strong positive cor-
relation between the level of angiotensin II and that of
peripheral vascular resistance. The TREND study21 and
Vanhoutte, Boulanger, and Monbouli22 also demon-
strated that substances inhibiting angiotensin II synthe-
sis can restore endothelium-dependent vasodilatation.
Finally, placenta has been considered as a major site for
the conversion of angiotensin, which in turn could con-
trol the local placental flow.23 Whereas angiotensin
constricted the umbilical-placental and the renal circu-
lations (to redistribute blood flow to the myocardi-
um),24 the renin-angiotensin system may also be an
important factor in the fetal response to stress.
Even though our data confirm the benefits of pul-
satile flow for up to 1 hour of bypass, the perfusion
remains lower than optimal, as indicated by the level
of lactate. Significant lactic acidosis developed as
soon as hysterotomy, fetal mobilization, and inci-
sions for arterial and venous line placement were
performed, and it kept increasing after sternotomy
and cannulation. This was most certainly the conse-
quence of metabolic debt due to fetal stress,25
including anesthetic procedures.26 Hypoxemia and
anemia due to fetal blood replacement by adult
hemoglobin with a lower affinity for oxygen than
fetal hemoglobin are other contributing factors.27
Under pulsatile-flow bypass, the lactate level
remained stable as opposed to the continuous
increase observed in steady-flow bypass. As lactate
release into the maternal circulation was not differ-
ent between the initiation of bypass and the end of
bypass, the rise in fetal lactate comes from the fetus
itself. The placenta may play an important role in
regulating circulating lactate concentrations under
hypoxic conditions,28 allowing the fetus to maintain
stable lactate concentration. However, a reduction in
placental blood flow impedes lactate clearance from
the fetal circulation.
Given the cannula size limitation, high physiologic
blood flows (400 mL · kg–1) that would possibly con-
trol the lactate level as described by Hawkins and
associates29,30 could not be achieved and total flows
ranged to a maximum of two thirds of normal expect-
ed flow. Finally, the choice of the pulse frequency
was dictated by the characteristics of the Harvard
pump, with an important residual volume and a back-
flow that imposed on us a relatively low frequency,
the physiologic heart rate being 140 to 180 beats ·
min–1 in these animals.
A different pump concept offering high beat rate, low
prime pulsatile flow, and limited backflow is currently
being developed for use in such specific settings.
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